Spondyloarthritis & psoriatic arthritis
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
Authors' conclusion
Uptake of newer b/tsDMARDs occurred mainly in biologic-experienced patients. Regardless of mode of action, only a minority of patients starting a second or later b/tsDMARD course remained on drug and achieved LDA.
Study context
- Population
- Patients with psoriatic arthritis (PsA) starting a b/tsDMARD in 2012–2020 in five Nordic rheumatology registerstreatment courses: 5659 adalimumab, 4767 newer b/tsDMARD
- Exposure
- Newer b/tsDMARDs vs adalimumab
- Adalimumabn = 5,659reference
- Outcome
- One-year retention and 6-month effectiveness (proportion achieving LDA on DAPSA28)
- Follow-up
- 1 year (retention); 6 months (LDA)
Methodological detailsmultinational registry-based, five Nordic rheumatology registers, adjusted regression models stratified by treatment course
- Multinational registry-based
- Five Nordic rheumatology registers
- Adjusted regression models stratified by treatment course
Main finding
As reported in the abstract
| Group | Retention rate | Low disease activity (LDA) |
|---|---|---|
| Adalimumab | 65% | 59% |
| Abatacept | 45% | 37% |
| Apremilast | 43% | 35% |
| Ixekizumab | 40% | |
| Ustekinumab | 40% |
Retention rate
Adalimumab65%
Abatacept45%
Apremilast43%
Ixekizumab— not stated in the abstract
Ustekinumab— not stated in the abstract
Low disease activity (LDA)
Adalimumab59%
Abatacept37%
Apremilast35%
Ixekizumab40%
Ustekinumab40%
Observational data: associations, not effects.
Further findings
Biologic-naïve courses
Uptake of newer b/tsDMARDs
- Increased from 2014 and plateaued in 2018
- Adalimumab more often first course; newer b/tsDMARDs more often in biologic-experienced patients
Original publication
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. Published 22 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →